LEXX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2026Q2

FY2026Q3

100.00K

-45.63%

-0.130

-18.75%

100.00K

-42.53%

-0.120

-20%

100.00K

-42.53%

-0.110

-47.62%

Estimates Revision

The market is revising Downward the revenue expectations for Lexaria Bioscience Corp. (LEXX) for FY2026, with the revenue forecasts being adjusted by -32.89% over the past three months. During the same period, the stock price has changed by -12.92%.

Revenue Estimates for FY2026

Revise Downward

-32.89%

In Past 3 Month

EPS Estimates for FY2026

Revise Upward

+17.65%

In Past 3 Month

Stock Price

Go Down

-12.92%

In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Lexaria Bioscience Corp (LEXX.O) is -1.64, compared to its 5-year average forward P/E of -3.32. For a more detailed relative valuation and DCF analysis to assess Lexaria Bioscience Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.32

Current PE

-1.64

Overvalued PE

-0.62

Undervalued PE

-6.03

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.83

Current EV/EBITDA

0.10

Overvalued EV/EBITDA

1.05

Undervalued EV/EBITDA

-2.70

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

45.41

Current PS

20.75

Overvalued PS

72.25

Undervalued PS

18.56

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

LEXX News & Events

Events Timeline

No data

News

6.0

2025-12-26Benzinga

HC Wainwright Raises Agios Price Target to $62

7.5

2025-12-26NASDAQ.COM

Galectin Secures $10M Credit Line, FDA Provides Guidance on Regulatory Pathway

9.0

2025-12-24NASDAQ.COM

Lexaria Achieves Primary Endpoint in GLP-1-H24-4 Study with Significant Safety Results

People Also Watch

Frequently Asked Questions

What is Lexaria Bioscience Corp (LEXX) stock price today?

The current price of LEXX is 0.746 USD — it has increased 7.34 % in the last trading day.

What is Lexaria Bioscience Corp (LEXX)'s business?

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery formulation and processing platform technology improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. The Company’s segment includes Intellectual Property, B2B Production, and Research and Development. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its focus is the investigation and the incorporation of its DehydraTECH drug delivery technology with glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) to enhance absorption and reduce adverse side effects. The Company operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 48 patents granted and many patents pending worldwide.

What is the price predicton of LEXX Stock?

Wall Street analysts forecast LEXX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEXX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Lexaria Bioscience Corp (LEXX)'s revenue for the last quarter?

Lexaria Bioscience Corp revenue for the last quarter amounts to 174.00K USD, increased 107.14 % YoY.

What is Lexaria Bioscience Corp (LEXX)'s earnings per share (EPS) for the last quarter?

Lexaria Bioscience Corp. EPS for the last quarter amounts to -0.14 USD, decreased -0.00 % YoY.

What changes have occurred in the market's expectations for Lexaria Bioscience Corp (LEXX)'s fundamentals?

How many employees does Lexaria Bioscience Corp (LEXX). have?

Lexaria Bioscience Corp (LEXX) has 7 emplpoyees as of January 10 2026.

What is Lexaria Bioscience Corp (LEXX) market cap?

Today LEXX has the market capitalization of 18.57M USD.